Regression of Atherosclerosis in ApoE-/- Mice Via Modulation of Monocyte Recruitment and Phenotype, Induced by Weekly Dosing of a Novel "Cytotopic" Anti-Thrombin Without Prolonged Anticoagulation.
Daxin Chen,Ke Li,Sam Festenstein,Julieta Karegli,Hannah Wilkinson,Hugh Leonard,Lin‐Lin Wei,Ning Ma,Min Xia,Henry Tam,Jian‐an Wang,Qingbo Xu,John H. McVey,Richard A. G. Smith,Anthony Dorling
DOI: https://doi.org/10.1161/jaha.119.014811
IF: 6.106
2020-07-03
Journal of the American Heart Association
Abstract:Background Anticoagulants induce atherosclerosis regression in animal models but exploiting this clinically is limited by bleeding events. Here we test a novel thrombin inhibitor, PTL060, comprising hirulog covalently linked to a synthetic myristoyl electrostatic switch to tether to cell membranes. Methods and Results ApoE−/− mice were fed chow or high‐fat diets, before transplantation of congenic aortic segments or injection of PTL060, parental hirulog, control saline, or labeled CD11b positive cells. Aortic transplants from transgenic mice expressing anticoagulants on endothelium did not develop atherosclerosis. A single intravenous injection of PTL060, but not hirulog inhibited atheroma development by >50% compared with controls when assessed 4 weeks later. Mice had prolonged bleeding times for only one seventh of the time that PTL060 was biologically active. Repeated weekly injections of PTL060 but not hirulog caused regression of atheroma. We dissected 2 contributory mechanisms. First, the majority of CCR2+ (C‐C chemokine receptor type 2+) monocytes recruited into plaques expressed CCR7 (C‐C chemokine receptor type 7), ABCA1 (ATP‐binding cassette transporter – 1), and interleukin‐10 in PTL060 mice, a phenotype seen in <20% of CCR2+ recruits in controls. Second, after several doses, there was a significant reduction in monocyte recruits, the majority of which were CCR2‐negative with a similar regression‐associated phenotype. Regression equivalent to that induced by intravenous PTL060 was induced by adoptive transfer of CD11b+ cells pre‐coated with PTL060. Conclusions Covalent linkage of a myristoyl electrostatic switch onto hirulog in PTL060 uncouples the pharmacodynamic effects on hemostasis and atherosclerosis, such that plaque regression, mediated predominantly via effects on monocytes, is accompanied by only transient anticoagulation. Nonstandard Abbreviations and Acronyms ABCA1 ATP‐binding cassette transporter – 1 BL/6 C57BL/6 mice CCL2 chemokine (C‐C motif) ligand 2 CCR2 C‐C chemokine receptor type 2 CCR7 C‐C chemokine receptor type 7 CD31‐Hir‐Tg a strain of transgenic mice expressing membrane tethered hirudin under CD31 promoter EC endothelial cell HFD high‐fat diet HLL chemically modified hirulog analogue hTFPI human tissue factor pathway inhibitor iNOS inducible NO synthase MIF macrophage migration inhibitory factor PAR protease‐activated receptor SMC smooth muscle cell TF tissue factor Clinical Perspective What Is New? We have developed a novel direct anti‐thrombin inhibitor specifically to target inflammatory processes, by covalently linking a synthetic myristoyl electrostatic switch (for cell‐membrane localization) to hirulog. Upon intravenous injection, it has the same anti‐coagulant profile as equimolar hirulog, but the membrane‐localizing component promotes prolonged localization on circulating leukocytes and vascular endothelium. This novel therapeutic induces regression of atherosclerosis in ApoE−/− mice after weekly intravenous dosing, by mechanisms that are dependent on this pattern of prolonged binding to cells within the vasculature; throughout treatment, mice are systemically anticoagulated for only 1 day out of 7. What Are the Clinical Implications? For the first time we have defined a way to uncouple the effects of hirulog on hemostasis from its effects on atheroma formation. Alongside our description -Abstract Truncated-
cardiac & cardiovascular systems